AmiGuard CT

Protection from the unintended consequences of CT scanning

AmiGuard CT™  is a low dose of the FDA-approved drug Amifostine, administered just once or twice, before and/or after a CT scan. Our solution helps to prevent RIGDI (radiation-induced genomic damage and instability)—a side effect of exposure to ionizing radiation, such as the radiation present in CT scans. RIGDI is a precursor to carcinogenesis. 

Read on to learn why this product is so important.

The Problem: CT Scans are critical to patient care, but CT scanning increases the risk of cancer

CT scans offer advanced imaging capabilities that have become an important part of identifying and monitoring medical conditions and assessing response to treatment.

Between 1980 and 2018, there was a 20x increase in the use of CT scan examinations, including more use of double scans (with and without contrast) in a single session. CT scan utilization continues to grow annually by more than 10%. Nearly 25% of people in the US now have at least one CT scan per year.

The challenge is that this advancement in image quality and escalating usage has come with a significant increase in ionizing radiation exposure. A single chest scan can deliver more than 350x the radiation of a standard x-ray.

Research shows that this type of radiation may damage a patient’s DNA and lead to carcinogenesis. More on the science behind this.

1 in 270 women and 1 in 600 men who undergo CT coronary angiography at age 40 will develop cancer as a result; the risk doubles at age 20.

And the effects of radiation are cumulative.

Children and women are most at risk.

The Solution: Reduce cancer risk with a low, preventative dose of Amifosine at time of CT scan.

AmiGuard CT is the first pharmaceutical solution for protection from CT scan radiation exposure.

In this patented application, patients take a low, easily-tolerated dose (25-100 mg/m2) of FDA-approved Amifostine once before and once after a CT scan.

AmiGuard CT is one-tenth of the dose of Amifostine already approved by the FDA, administered on a single day of treatment, compared with typical current usage of 250-1000 mg/m2 taken 5 times per week for 6-7 weeks.

AmiGuard CT protects human cells and tissues from chromosomal damage and instability caused by CT scan radiation, which is a precursor to carcinogenesis, and enhances the fidelity of repair of those cells.

F3’s Innovation Path

With FDA approval, F3 will first introduce AmiGuard CT for scans of the chest, pelvis and/or abdomen, with dosage administered in the IV already required for the contrast material used for the CT scan.

Soon thereafter, F3 will target AmiGuard CT for broader IV administration for all types of CT scans, with subcutaneous and oral administration methods to follow.

Learn about the Science of AmiGuard CT

What’s next